{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 23,
  "pageCount": 53,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "This appears to be a page from a formal investigative report or legal document.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/23",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-23",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Jeff - think it would be great for you or Sastry to talk about our work w FDA, specifically sentinel which I think would be v useful for them in opioids.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49b-811019825828",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.15,
        "y": 0.8
      },
      "kind": "disclaimer",
      "text": "107 MCK-HCOR-0125427, Slide 6.\n108 MCK-HCOR-0174550 to MCK-HCOR-0174698 (McKinsey Purdue Engagement List).\n109 Real World Evidence reflects data regarding the usage and potential benefits or risks of a medical product derived outside the clinical trial process from sources such as billing records, patient data, and disease registries. Food and Drug Administration, Real-World Evidence (online at www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence) (accessed on Mar. 16, 2022).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9c09a32-e0b5-4d44-acb7-39b8c03aa2c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.15,
        "y": 0.36
      },
      "kind": "paragraph",
      "text": "In May 2016, while working on the FDA's Sentinel program, Mr. Smith assisted a team of McKinsey consultants in preparing a new proposal to submit to Purdue for a project designed to provide \"real world evidence\" of OxyContin's safety, through which McKinsey would provide data on the drug's safety from patient-generated and public health data outside of clinical trials.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30724d7b-c2dc-42c2-829c-3969f5af0b59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.27
      },
      "kind": "paragraph",
      "text": "Documents obtained by the Committee reveal that McKinsey consultants representing Purdue sought out information from consultants representing FDA, who may have shared details about the FDA Sentinel Initiative with Purdue with the goal of securing a contract to track OxyContin's safety.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86df7ed7-86f6-4d6a-97cc-8eaec12b0058",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.59
      },
      "kind": "quote",
      "text": "\"Jeff - think it would be great for you or Sastry to talk about our work w FDA, specifically sentinel which I think would be v useful for them in opioids.\"\n— A. Ghatak, McKinsey Partner",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47ba5794-8358-4214-9b13-58adf483721b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Jeff - think it would be great for you or Sastry to talk about our work w FDA, specifically sentinel which I think would be v useful for them in opioids. — A. Ghatak, McKinsey Partner",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49b-879fc8adb26c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.15,
        "y": 0.22
      },
      "kind": "title",
      "text": "2. Increased Risk that McKinsey Shared Information About FDA's Sentinel Contract to Gain Additional Work at Purdue",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a4c2ec0-1d6b-40b0-b17a-b66f34265496",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 6,
      "beatId": "ca9c3ab4-903c-4ff0-b53d-42335d2ce596",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents extensive evidence of McKinsey's conflicts of interest, including consultant overlaps and contract details.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}